Abstract
Direct thrombin inhibitors represent a new class of anticoagulants that bind directly to thrombin and block the enzymes interactions with its substrates. These agents have been developed, at least in part, to overcome the limitations of heparin and vitamin K antagonists. This paper (a) reviews why thrombin is an ideal target for new anticoagulants, (b) describes the pharmacological profiles of the various direct thrombin inhibitors, (c) outlines the potential mechanistic advantages of parenteral direct thrombin inhibitors over heparin, (d) defines the potential benefits of ximelagatran, the first orally active direct thrombin inhibitor, over vitamin K antagonists, and (e) provides clinical perspective on the strengths and weaknesses of the various parenteral and oral direct thrombin inhibitors.
Keywords: Anticoagulants, thromboxane, heparin-induced thrombocytopenia (HIT), Hirudin, Ximelagatran, Vitamin K antagonists
Current Pharmaceutical Design
Title: Pharmacology and Clinical Potential of Direct Thrombin Inhibitors
Volume: 11 Issue: 30
Author(s): L- A. Linkins and J. I. Weitz
Affiliation:
Keywords: Anticoagulants, thromboxane, heparin-induced thrombocytopenia (HIT), Hirudin, Ximelagatran, Vitamin K antagonists
Abstract: Direct thrombin inhibitors represent a new class of anticoagulants that bind directly to thrombin and block the enzymes interactions with its substrates. These agents have been developed, at least in part, to overcome the limitations of heparin and vitamin K antagonists. This paper (a) reviews why thrombin is an ideal target for new anticoagulants, (b) describes the pharmacological profiles of the various direct thrombin inhibitors, (c) outlines the potential mechanistic advantages of parenteral direct thrombin inhibitors over heparin, (d) defines the potential benefits of ximelagatran, the first orally active direct thrombin inhibitor, over vitamin K antagonists, and (e) provides clinical perspective on the strengths and weaknesses of the various parenteral and oral direct thrombin inhibitors.
Export Options
About this article
Cite this article as:
Linkins A. L- and Weitz I. J., Pharmacology and Clinical Potential of Direct Thrombin Inhibitors, Current Pharmaceutical Design 2005; 11 (30) . https://dx.doi.org/10.2174/138161205774580598
DOI https://dx.doi.org/10.2174/138161205774580598 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“Impact of Smoking Cessation Treatment” on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study
Recent Patents on Anti-Cancer Drug Discovery Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design The Use of Exercise Echocardiography in the Evaluation of Mitral Regurgitation
Current Cardiology Reviews Pharmacological Therapies for Pediatric and Neonatal ALI/ARDS: An Evidence-Based Review
Current Drug Targets Editorial (Hot Topic:Current Situation at Perioperative of Cardiovascular Disease Patients: New Addressing and Perioperative Optimization Techniques)
Current Pharmaceutical Design Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Use of Bipolar Radiofrequency Catheter Ablation in the Treatment of Cardiac Arrhythmias
Current Cardiology Reviews Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Alzheimer’s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome
Current Neuropharmacology Postconditioning: A New Paradigm for Myocardial Protection?
Current Cardiology Reviews Involvement of P-glycoprotein and Multidrug Resistance Associated Protein 1 in the Transport of Tanshinone IIB, a Primary Active Diterpenoid Quinone from the Roots of Salvia miltiorrhiza, Across the Blood-Brain Barrier
Drug Metabolism Letters Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets The Evolving Roles of Nuclear Cardiology
Current Cardiology Reviews The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry Cigarette Smoke-Induced Proteostasis Imbalance in Obstructive Lung Diseases
Current Molecular Medicine Chagas Heart Disease Pathogenesis: One Mechanism or Many?
Current Molecular Medicine Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science